Combined Therapy Potential of Apocynin and Tert-butylhydroquinone as a Therapeutic Agent to Prevent Secondary Progression to Traumatic Brain Injury.
Apocynin
NADPH oxidase 2
nuclear factor erythroid 2-like 2
tert-butylhydroquinone
traumatic brain injury
Journal
Asian journal of neurosurgery
ISSN: 1793-5482
Titre abrégé: Asian J Neurosurg
Pays: India
ID NLM: 101564712
Informations de publication
Date de publication:
Historique:
received:
19
07
2019
accepted:
23
01
2020
entrez:
18
3
2020
pubmed:
18
3
2020
medline:
18
3
2020
Statut:
epublish
Résumé
Traumatic brain injury is caused by physical collision (primary injury). It changes the brain's biochemistry and disturbs the normal brain function such as memory loss and consciousness disturbance (secondary injury). The severity can be measured with the Glasgow Coma Scale. The secondary injury will cause oxidative stress that leads to the nervous cells death, so treatment is needed before it gets worse. Primary injury results in excess of reactive oxidative stress (ROS) which is known from NADPH oxidase 2 (Nox2). Excessive ROS is deadly to the nerve cells. Excessive ROS will activate nuclear factor erythroid 2-like 2 (Nrf2). Nrf2 will bind to antioxidant response elements, to protect multi organs against ROS, including this brain injury. However, this does not last long, so it requires handling excess ROS.
Identifiants
pubmed: 32181166
doi: 10.4103/ajns.AJNS_231_19
pii: AJNS-15-10
pmc: PMC7057894
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
10-15Informations de copyright
Copyright: © 2020 Asian Journal of Neurosurgery.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Injury. 2011 Jul;42(7):714-8
pubmed: 21466884
Neurochem Int. 2014 Apr;69:14-9
pubmed: 24589771
Handb Clin Neurol. 2014;124:271-90
pubmed: 25248593
Exp Lung Res. 2012 Mar;38(2):90-9
pubmed: 22296407
Mol Med Rep. 2013 Jan;7(1):327-31
pubmed: 23128834
Brain Res. 2012 Oct 24;1481:49-58
pubmed: 22975130
Cell Mol Neurobiol. 2017 May;37(4):571-585
pubmed: 27383839
Int J Mol Sci. 2014 Jan 17;15(1):1216-36
pubmed: 24445258
JAMA Neurol. 2015 Mar;72(3):355-62
pubmed: 25599342
Mt Sinai J Med. 2009 Apr;76(2):97-104
pubmed: 19306379
J Child Neurol. 2016 Jan;31(1):20-7
pubmed: 25123531
J Trauma Acute Care Surg. 2015 Jan;78(1):184-91
pubmed: 25539220
J Cereb Blood Flow Metab. 2018 Oct;38(10):1818-1827
pubmed: 29083257
J Neurotrauma. 2009 Nov;26(11):1857-66
pubmed: 19508156
J Clin Exp Neuropsychol. 2015;37(4):439-54
pubmed: 26000663
Neurochem Res. 2015 Sep;40(9):1829-38
pubmed: 26260377
Oxid Med Cell Longev. 2015;2015:370312
pubmed: 25918580
Neuropsychiatr Dis Treat. 2015 Jan 08;11:97-106
pubmed: 25657582
Neurochem Int. 2013 Nov;63(6):583-93
pubmed: 24076474
Front Biosci (Elite Ed). 2012 Jan 01;4(6):2183-93
pubmed: 22202030
Neurochem Int. 2017 Dec;111:32-44
pubmed: 28465088
Acta Pharmacol Sin. 2010 Nov;31(11):1421-30
pubmed: 20953205
Biochim Biophys Acta. 2015 Apr;1850(4):794-801
pubmed: 25484314
Handb Clin Neurol. 2015;127:3-13
pubmed: 25702206
J Surg Res. 2014 May 1;188(1):206-12
pubmed: 24387843
World Neurosurg. 2014 Mar-Apr;81(3-4):478-82
pubmed: 23954733
J Neurotrauma. 2012 Apr 10;29(6):1188-96
pubmed: 22201269
Neurochem Res. 2017 Nov;42(11):3296-3309
pubmed: 28786047
Brain Behav Immun. 2012 Nov;26(8):1191-201
pubmed: 22728326
Expert Opin Emerg Drugs. 2009 Mar;14(1):67-84
pubmed: 19249984
Neurosurgery. 2017 Jan 01;80(1):6-15
pubmed: 27654000
Expert Opin Ther Targets. 2010 Mar;14(3):329-46
pubmed: 20148719
Acta Neurochir (Wien). 2015 Oct;157(10):1683-96
pubmed: 26269030